/ dementia
Promoting Dignity And Independence For People Who Suffer From Dementia published
Fri, 09 May 2008 01:00:00 PDT
Two projects by South Essex Partnership NHS Foundation Trust (SEPT) to promote dignity and independence for people who suffer from dementia were highly commended at this year's East of England Health and Social Care Awards. The innovative projects 'Lasting Memories' and 'My life Story' were launched in December 2007 and work closely with patients, their carers, families and friends to improve their quality of life.
Molecules In Plants May Have Beneficial Effect On Alzheimer's Disease published
Fri, 09 May 2008 00:00:00 PDT
A set of molecules found in certain plants appears to have a beneficial effect in brain tissue associated with Alzheimer's disease, according to a new study conducted in mice. The study was led by researchers at the University of South Florida and Cedars-Sinai Medical Center. An article in the Journal of Cellular and Molecular Medicine is available online.Terrence Town, Ph.D., one of the senior authors of the study, is available to provide more information about this study.
Obesity Linked To Increased Risk For Dementia published
Fri, 09 May 2008 00:00:00 PDT
Obesity may increase adults' risk for having dementia, according to researchers at the Johns Hopkins Bloomberg School of Public Health. Their analysis of published obesity and dementia prospective follow-up studies over the past two decades shows a consistent relationship between the two diseases. The results are published by The International Association for the Study of Obesity in the May, 2008 issue of Obesity Reviews.
Alzheimer's Disease: Modulating Enkephalin May Reduce Cognitive Deficits published
Thu, 08 May 2008 03:00:00 PDT
Alzheimer's disease (AD) is an incurable disease that is increasing in prevalence and will increase even more rapidly as the Baby Boom generation enters the age of highest risk. The available AD drugs are only partially effective in some patients. New strategies are urgently needed.
Patent Claims Allowed Covering Samaritan's Alzheimer's Memory Recovery Drug In Australia published
Thu, 08 May 2008 02:00:00 PDT
Samaritan Pharmaceuticals (OTCBB:SPHC), a biopharmaceutical company committed to commercializing new innovative therapeutic drugs, has received notification that the claims in the patent application for "Neuroprotective Spirostenol Pharmaceutical Compositions" covering Caprospinol (SP-233) have been allowed by the Australian Patent Office. The hallmark of Alzheimer's disease is plaque formation in areas of the brain that control memory and thinking skills.
Obesity Significantly Raises Dementia Risk - Underweight Also Raises Risk published
Thu, 08 May 2008 01:00:00 PDT
Being obese can increase the risk of Alzheimer's Disease by as much as 80 percent, according to a study in the May issue of Obesity Reviews.But it's not just weight gain that poses a risk. People who are underweight also havean elevated risk of dementia, unlike people who are normal weight or overweight.
EPIX Pharmaceuticals Initiates Phase 2b Program In Alzheimer's Disease published
Wed, 07 May 2008 03:00:00 PDT
EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, today announced that it has begun its Phase 2b program in Alzheimer's disease through the initiation of a clinical trial of PRX-03140, its novel 5-HT4 agonist, in combination with donepezil (AriceptŪ).
Ibuprofen Linked To Reduced Alzheimer's Risk published
Tue, 06 May 2008 00:00:00 PDT
Researchers in the US studying a large patient population have shown that use of the anti-inflammatory and painkiller ibuprofen is linked to lower risk of developing Alzheimer's disease. Patients who used the drug for more than 5 years were 40 per cent less likely to develop the disease compared with patients who did not use that type of drug at all.
Anti-Inflammatory Drug - Alzheimer's Society Comment published
Mon, 05 May 2008 02:00:00 PDT
Alzheimer's Society comment on new research suggesting tarenflurbil may be effective in halting symptoms of Alzheimer's disease, from the Lancet Neurology. 'This exciting clinical trial suggests a modification of a safe and readily available anti-inflammatory drug has a positive impact on memory and function for people with mild Alzheimer's disease.
Alzheimer Scotland Supports Appeal Judgment On NICE Cost-effectiveness Disclosure published
Mon, 05 May 2008 01:00:00 PDT
The Court of Appeal ruled in favour of the drug companies Pfizer and Eisai, by finding that the National Institute for Health and Clinical Excellence (NICE) should have allowed public access to the health economics model used to determine the cost-effectiveness of key treatments in people with early stage Alzheimer's. Three judges found that the process by which NICE decided to restrict the anti-dementia medicines for newly diagnosed patients with mild Alzheimer's was procedurally unfair.
Sleep Disturbances Among Alzheimer Patients, Caregivers Show A Significant Difference published
Fri, 02 May 2008 05:00:00 PDT
A study published in the May 1 issue of the journal SLEEP finds that sleep disturbances among Alzheimer patients vary significantly from those of their family caregivers, and that, surprisingly, poor sleep in either the patient or caregiver is not necessarily linked to disturbed sleep in the other.Susan M.
Alzheimer Scotland Welcomes Promising Early Findings From Tarenflurbil Study published
Fri, 02 May 2008 04:00:00 PDT
Alzheimer Scotland welcomes the recent findings from Professor Gordon Wilcock's randomised phase II trial of tarenflurbil in patients with mild to moderate Alzheimer's Disease, but cautions that the phase III stage will be crucial in ascertaining its true potential. The Oxford-based scientists, working with researchers across the world, found that there was a dose-related effect on measures of daily activities and function in patients with mild Alzheimer's Disease.
Renewed Hope For Mild Alzheimer's Patients As NICE Process On Anti-Dementia Medicines Ruled Unfair, UK published
Fri, 02 May 2008 02:00:00 PDT
Eisai Limited, the licence holder of Aricept(R) (donepezil hydrochloride) and Pfizer Limited, its co-promotion partner, welcomed today's landmark ruling by the Court of Appeal. The Court found that the process by which the National Institute for Health and Clinical Excellence (NICE) decided to restrict anti-dementia medicines for newly diagnosed patients with mild Alzheimer's disease was procedurally unfair.
Risk Factors For Dementia Are Different Between Men And Women published
Thu, 01 May 2008 16:00:00 PDT
According to a study published in the Journal of NeurologyNeurosurgery and Psychiatry,men and women have different risk factors that contribute to thedevelopment of Alzheimer's disease and dementia. The French researchersfoundthat stroke is a main risk factor for men and depression is a criticalfactor for women.The researchers analyzed a sample of almost 7000 people over age 65from three French cities.
Men And Women Have Different Dementia Risks published
Thu, 01 May 2008 12:00:00 PDT
New research from France suggests that men and women have different risks for mild cognitive impairment (MCI) and progression to dementia. The researchers suggest stroke is a primary risk factor for men, and depression for women.
Diabetes And Alzheimer's Disease Linked By Salk Institute Study published
Thu, 01 May 2008 02:00:00 PDT
Diabetic individuals have a significantly higher risk of developing Alzheimer's disease but the molecular connection between the two remains unexplained. Now, researchers at the Salk Institute for Biological Studies identified the probable molecular basis for the diabetes - Alzheimer's interaction.In a study published in the current online issue of Neurobiology of Aging, investigators led by David R. Schubert, Ph.D.
Tarenflurbil Trial Encouraging For Mild Alzheimer's Disease Patients published
Wed, 30 Apr 2008 17:00:00 PDT
An article published in The Lancet Neurologyrecommends a phase III study for the drug tarenflurbil, amedication given to patients with mild Alzheimer's disease (AD). Thephase II study found that patients who took 800 mg of tarenflurbiltwice daily had better functional ability results than patients takingplacebo.
Presentations From 'Intracellular Traffic And Neurodegenerative Disorders' Meeting published
Wed, 30 Apr 2008 01:00:00 PDT
The 23rd Colloque Medecine et Recherche of La Fondation Ipsen dedicated to the Alzheimer series was held in Paris on 28 April 2008. Entitled "Intracellular Traffic and Neurodegenerative Disorders" this meeting gathered fourteen leading researchers focused on the intracellular world.
Journal Of Alzheimer's Disease Annual Award For Outstanding Contribution To Be Awarded To Milan Fiala, MD published
Tue, 29 Apr 2008 06:00:00 PDT
Milan Fiala, MD, UCLA Orthopedic Hospital, has been chosen as the recipient of the 2008 Alzheimer Award presented by the Journal of Alzheimer's Disease in recognition of his outstanding work, "Phagocytosis of amyloid-beta and inflammation: Two faces of innate immunity in Alzheimer's disease" by M. Fiala, D.H. Cribbs, M. Rosenthal and G. Bernard (July 2007, JAD 11(4): 457-63).
Investigators Unveil New Drug Discovery Tool For Alzheimer's Disease published
Tue, 29 Apr 2008 04:00:00 PDT
An article published in the April issue of the Journal of Alzheimer's Disease presents a detailed characterization of a new drug discovery tool for Alzheimer's disease. It demonstrates that an abnormal form of tau protein, as it occurs in Alzheimer's disease, can be produced in very simple cell models in an unambiguous way. Most importantly, it also shows an example of a chemical compound, found in nature, which is highly effective to completely suppress the abnormal changes of tau.
Alzheimer Scotland Welcomes Sutherland Report On Free Personal Care published
Tue, 29 Apr 2008 01:00:00 PDT
Alzheimer Scotland welcomes this landmark review which endorses the policy of free personal care for older people. Jim Jackson, Chief Executive, Alzheimer Scotland, said: "There is no cure for dementia, but the provision of personal care is as necessary for the health and well being of people with this devastating illness as medical treatment is for cancer patients.
MPs Highlight Abuse Of Human Rights Of People With Dementia, UK published
Tue, 29 Apr 2008 01:00:00 PDT
An influential group of MPs is calling on the Government to stop the dangerous over-prescribing of antipsychotic drugs to people with dementia. Up to 105,000 people with dementia are given the drugs inappropriately, according to expert predictions in the new All-Party Parliamentary Group (APPG) on Dementia report, 'Always A Last Resort', published recently.
Anesthesia, Alzheimer's And Low Oxygen published
Mon, 28 Apr 2008 02:00:00 PDT
In studies of human brain cells, the widely-used anesthetic desflurane does not contribute to increased production of amyloid-beta protein; however, when combined with low oxygen conditions, it can produce more of this Alzheimer's associated protein.Over 200 million people undergo surgery each year, and there has been concern that anesthetic use may contribute to Alzheimer's and other brain disorders.
Black, Hispanic Caregivers More Likely To Misinterpret Signs Of Alzheimer's, Survey Finds published
Fri, 25 Apr 2008 07:00:00 PDT
Hispanic and black caregivers are more likely than other ethnic groups to misinterpret symptoms of Alzheimer's disease as normal signs of aging, according to a recent survey by the Alzheimer's Foundation of America, HealthDay/Washington Post reports.
Targeting Cell Membrane RAFTS Offers Novel Approach To Treat Alzheimer's And Other Diseases published
Fri, 25 Apr 2008 03:00:00 PDT
JADO Technologies GmbH, the leading developer of RAFT intervention therapeutics, has announced he publication of a paper in Science demonstrating a potential novel strategy for therapeutic intervention in Alzheimer's and other diseases by targeting discrete sub-compartments in the cell membrane (RAFTS). The study conducted by JADO scientists together with several academic collaborators will appear in the April 25, 2008 issue of the magazine.
|
|
